Avecho and Sandoz Partner in Landmark $19M Deal to Develop OTC CBD Insomnia Treatment
Key Insights
Avecho Biotechnology (search) and Sandoz have signed a 10-year exclusive licensing agreement worth up to US$19 million to develop and commercialize a CBD-based insomnia (search) treatment for the Australian market.
The agreement includes a US$3 million upfront payment and potential milestone payments of US$16 million, plus tiered royalties of 14-19% on net sales, targeting Australia's estimated US$125 million OTC CBD market.
The pharmaceutical CBD capsule aims to become Australia's first TGA-registered over-the-counter CBD medicine for insomnia (search), addressing a significant medical need affecting 9.5 million Australians.
Avecho Biotechnology (search) has secured a major pharmaceutical partnership with Sandoz Group AG in a deal potentially worth US$19 million to develop and commercialize an innovative CBD-based treatment for insomnia (search) in Australia. The exclusive ten-year agreement marks a significant step toward bringing the first TGA-registered over-the-counter CBD medicine to Australian patients.
Deal Structure and Financial Terms
The partnership includes an immediate upfront payment of US$3 million (approximately A$4.8 million) to Avecho, with additional development milestone payments of up to US$16 million available before commercial launch. Once the product reaches the market, Avecho will receive tiered royalties ranging from 14% to 19% on net sales, representing a substantial ongoing revenue opportunity.
Under the terms of the agreement, Sandoz gains exclusive commercial rights for the Australian market, while Avecho maintains rights in all other territories. The deal includes a right of first refusal for Sandoz should Avecho receive commercial offers for other markets. The initial ten-year term can be automatically extended for two additional two-year periods.
Development and Commercialization Strategy
Avecho will maintain responsibility for funding and overseeing the ongoing Phase III clinical trial for the CBD capsule. Following successful trial completion, both companies will collaborate to secure Therapeutic Goods Administration (TGA) approval. Sandoz will then take charge of commercialization efforts, including marketing and distribution, while purchasing the finished product directly from Avecho.
Market Opportunity and Medical Need
The development addresses a significant unmet medical need in Australia, where approximately 9.5 million people experience insomnia (search) symptoms, with 3.6 million suffering from chronic insomnia. Market analysts project the Australian over-the-counter CBD market could exceed US$125 million annually, indicating substantial commercial potential for the product.
Dr. Paul Gavin, CEO of Avecho, emphasized the strategic importance of the partnership, stating that the agreement strengthens the company's commercial prospects while improving access to insomnia (search) treatments in Australia. The collaboration leverages Sandoz's extensive pharmaceutical commercialization expertise while maintaining Avecho's development capabilities.
Regulatory and Market Implications
If successful, this CBD capsule will pioneer the over-the-counter CBD pharmaceutical market in Australia as the first TGA-registered product in its category. This regulatory achievement could set important precedents for future CBD-based medications and potentially influence regulatory approaches in other markets.